Quiet on the insider front: nobody at Oncocyte Corp bought or sold OCX shares in open-market trades this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
Quiet on the insider front: nobody at Oncocyte Corp bought or sold OCX shares in open-market trades this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 11, 2025 | James Andrea S. | CFO | Buy | 97,561 | $2.05 | $200K | SEC |
| Feb 11, 2025 | SMITH PATRICK W | 10% Owner | Buy | 1,077,600 | $2.05 | $2.2M | SEC |
| Feb 10, 2025 | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | 660,207 | $2.05 | $1.4M | SEC |
| Feb 10, 2025 | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | 4,505,488 | $2.05 | $9.2M | SEC |
| Feb 4, 2025 | SMITH PATRICK W | 10% Owner | Buy | 890 | $2.01 | $2K | SEC |
| Feb 4, 2025 | SMITH PATRICK W | 10% Owner | Buy | 25 | $2.02 | $50 | SEC |
| Jan 31, 2025 | SMITH PATRICK W | 10% Owner | Buy | 3,880 | $2.01 | $8K | SEC |
| Jan 31, 2025 | SMITH PATRICK W | 10% Owner | Buy | 318 | $2.01 | $639 | SEC |
| Jan 15, 2025 | SMITH PATRICK W | 10% Owner | Buy | 5,669 | $2.08 | $12K | SEC |
| Jan 15, 2025 | SMITH PATRICK W | 10% Owner | Buy | 100 | $2.08 | $208 | SEC |
| Jan 15, 2025 | SMITH PATRICK W | 10% Owner | Buy | 10,286 | $2.15 | $22K | SEC |
| Dec 27, 2024 | SMITH PATRICK W | 10% Owner | Buy | 90,219 | $2.13 | $192K | SEC |
| Dec 26, 2024 | Arno Andrew | Director | Buy | 12,500 | $2.11 | $26K | SEC |
| Dec 9, 2024 | James Andrea S. | CFO | Buy | 20,000 | $2.29 | $46K | SEC |
| Oct 4, 2024 | BROADWOOD CAPITAL INC | 10% Owner | Buy | 1,315,339 | $2.95 | $3.9M | SEC |
There were no open-market insider trades in OCX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in OCX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).